Clinical Minds

Adoption of new clinical trial technologies is critical to success. These innovations can lift patient burden, improve patient engagement, and increase equity and access to clinical trials. In this episode, Kelly McKee and Alicia Staley of Medidata are joined by Irfan Khan, MD, founder and CEO of Circuit Clinical, to discuss clinical trial technology adoption across patients, care teams, trial sites, and researchers and the need for industry buy-in, especially around decentralized trial technology. Dr. Khan is a cardiologist who has served as a principal investigator on both therapeutic and device clinical trials for more than a decade. He is passionate about improving diversity in clinical trials, increasing community engagement, and fostering the patient experience through education and empowerment. Over the last six years, he has overseen Circuit Clinical’s growth to reach more than 2.5 million potential participants across 60+ active research sites.

Is your product truly inspired by patient insights? Patient centricity is more than just a buzzword: it’s a movement. So how do you make sure your products improve the patient experience in clinical trials and alleviate patient burden? In this episode, industry experts Kelly McKee and Alicia Staley are joined by Paul Chang, VP of Design at Medidata, to map the future of product design in clinical trials. Learn how Medidata’s patient advocates directly impact UX design to drive patient centricity across products. Paul has spent over 20 years across a diverse range of product and design initiatives. In his role as VP of Design, he is responsible for how products and services are experienced by customers, partners, clinicians, and patients; this includes leading design strategy and building Medidata’s capabilities and reputation as a design-driven company.

The U.S. population is growing increasingly diverse and ensuring that we have meaningful representation of racial and ethnic minorities and other diverse populations in clinical trials for regulated medical products is fundamental not only to FDA's regulatory mission, but also public health,” Dr. Jovonni Spinner, Associate Director of Outreach and Communications at the FDA's Office of Minority Health and Health Equity. Related links https://www.fda.gov/about-fda/office-commissioner/office-minority-health-and-health-equity https://www.beaconpublichealth.com/

Currently our black and brown communities are really grossly underrepresented in cancer clinical trials, and we need to fix that. Historical barriers around egregious medical behaviors that have taken place in the past, cultural barriers, language barriers, and finally socioeconomic barriers impact the outcome of someone’s cancer journey,” says Dana Dornsife, founder and CEO at Lazarex Cancer Foundation, a nationwide non-profit org she founded in 2006.

Introducing Season 2 of Clinical Minds! An entire season dedicated to why diversity in clinical trials is so important and what’s being done to improve participation among underrepresented populations. To kick things off, host Paul Oestreicher chats with Jackie Kent, evp and chief customer officer at Medidata, a Dassault Systèmes

Dr. David Fajgenbaum, physician, scientist and author of the bestselling memoir, Chasing My Cure: A Doctor's Race to Turn Hope Into Action, on his approach to drug repurposing, how he and a team of volunteers have been applying this approach to Covid-19, and why this gives hope for all diseases with unmet need.

Anthony Costello, senior vice president of mobile health at Medidata, on what clinical trials look like when people are unable or unwilling to leave home, what this means for the race for a vaccine, and how mobile health technology is paving the way.

Clinical trials 101. Alicia Staley, director of patient engagement at Medidata, on why it takes so long to develop drugs and vaccines, what clinical trials are, and how clinical trials can do better for patients.